Latest News About Replimune Group

I don’t have live access to up-to-the-minute feeds right now, but here’s the latest I can provide based on recent publicly available reporting up to early 2026.

• Replimune Group (REPL) has been in the news for updates on RP1 in combination with nivolumab for advanced melanoma, including FDA interactions and path-to-approval discussions. Recent coverage notes a challenging regulatory path and ongoing updates on trial readouts and corporate financing efforts.[1][6]
• The regulatory environment has seen significant volatility, with reports of Complete Response Letters (CRLs) and reconsideration of accelerated approval pathways impacting investor sentiment and pipeline planning.[2][4]
• Company filings and press releases through 2025–2026 indicate continued emphasis on IGNYTE trial data, potential PDUFA timelines, and efforts to scale manufacturing and commercial readiness if a viable regulatory path emerges.[5][6][1]

If you’d like, I can compile a current digest with direct links to the latest press releases, SEC filings, and conference presentations, or set up a quick news alert for Replimune to capture new developments as they appear. Would you prefer a concise bullet digest or a structured table of recent milestones with dates?

Citations:

• Latest news coverage and summaries on Replimune’s RP1 and regulatory status.[1]
• Market/press reporting on FDA interactions and CRLs, including sentiment and potential impact.[4][2]
• Investor relations and recent filings detailing corporate updates and trial timelines.[6][5]